SCHEMBL758585

SCHEMBL758585

CN(C)C(=O)c1cc(Br)ccc1F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
AR P10275 1/20 0.47
DGAT1 O75907 1/20 0.46
CES2 O00748 2/20 0.46
GALR3 O60755 1/20 0.46
LMNA P02545 2/20 0.45
MAPT P10636 1/20 0.45
CYP1A2 P05177 3/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
CASP1 P29466 1/20 0.41
NCEH1 Q6PIU2 1/20 0.40
MYC P01106 1/20 0.40
NR4A1 P22736 1/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL646187 0.85 DGAT1 (0.59) ALDH1A1DGAT1CES2GALR3LMNA
SCHEMBL10909 0.83 ALDH1A1 (0.45) ALDH1A1DGAT1CES2GALR3LMNA
SCHEMBL8566777 0.81 CES2 (0.61) ALDH1A1ARCES2NPC1KMT2A
SCHEMBL31270828 0.81 CES2 (0.61) ALDH1A1ARCES2NPC1KMT2A
SCHEMBL3545870 0.79 ALDH1A1 (0.66) ALDH1A1CES2GALR3LMNAMAPT
SCHEMBL12261048 0.79 CES2 (0.68) ALDH1A1ARCES2GALR3LMNA
SCHEMBL254680 0.79 HPGD (0.55) ALDH1A1ARMAPTHPGDMYC
SCHEMBL3749047 0.79 AR (0.48) ALDH1A1ARCES2HPGDRAB9A
SCHEMBL10082 0.79 DGAT1 (0.50) ALDH1A1DGAT1CES2GALR3LMNA
SCHEMBL30374539 0.79 DGAT1 (0.50) ALDH1A1DGAT1CES2GALR3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353516-A1 IMINOTHIADIAZINE DIOXIDES CONTAINING A THIOAMIDE, AMIDINE, OR AMIDE OXIME GROUP AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME LLC 2015-12-10 US disclosed
US-20150353516-A1 IMINOTHIADIAZINE DIOXIDES CONTAINING A THIOAMIDE, AMIDINE, OR AMIDE OXIME GROUP AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME LLC 2015-12-10 US disclosed
US-20120289502-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-15 US disclosed
US-8273738-B2 Imidazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-09-25 US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
EP-2090570-B1 IMIDAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2011-11-09 EP disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed
US-6245761-B1 NERVOUS SYSTEM, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS ELI LILLY AND COMPANY 2001-06-12 US disclosed
CN-1173867-A Indolyl neuropeptide Y receptor antagonists LILLY CO ELI (US) 1998-02-18 CN disclosed
EP-0789688-A4 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS LILLY CO ELI (US) 1997-11-19 EP disclosed
EP-0789688-A1 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-08-20 EP disclosed
WO-1997009308-A1 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353516-A1 IMINOTHIADIAZINE DIOXIDES CONTAINING A THIOAMIDE, AMIDINE, OR AMIDE OXIME GROUP AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE2, BACE1, APP ALDH1A1 1703/4885AR 2423/4885DGAT1 1677/4885
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 ALDH1A1 89/4885AR 2184/4885DGAT1 2137/4885
US-20120289502-A1 IMIDAZOLE DERIVATIVES CNR1, CNR2, ARRB1 ALDH1A1 2997/4885AR 310/4885DGAT1 3468/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 ALDH1A1 89/4885AR 2184/4885DGAT1 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.